Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243247 | 1.00 | GPR119 (0.52) | GPR119NR1H2PRMT5WDR77HPGD | |
| SCHEMBL4097772 | 0.91 | GPR119 (0.60) | GPR119NR1H2HPGDRECQLEPHX1 | |
| SCHEMBL17656738 | 0.91 | GPR119 (0.47) | GPR119NR1H2PRMT5WDR77HPGD | |
| SCHEMBL15000982 | 0.91 | GPR119 (0.47) | GPR119NR1H2PRMT5WDR77HPGD | |
| SCHEMBL15885690 | 0.89 | NR1H2 (0.56) | GPR119NR1H2PRMT5WDR77HPGD | |
| SCHEMBL2149117 | 0.85 | GPR119 (0.58) | GPR119PRMT5WDR77HPGDRECQL | |
| SCHEMBL20303147 | 0.85 | GPR119 (0.58) | GPR119PRMT5WDR77HPGDRECQL | |
| SCHEMBL2676533 | 0.85 | GPR119 (0.58) | GPR119NR1H2HPGDMEN1ALDH1A1 | |
| SCHEMBL470837 | 0.85 | GPR119 (0.67) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL13677184 | 0.85 | PRMT5 (0.49) | GPR119NR1H2PRMT5WDR77HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2008005268-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | GPR119 4146/4885NR1H2 3487/4885PRMT5 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.